Subscribe to news

Cryonix CJSC

Cryonix operates in the biotech, pharmacological and medical sectors. The company’s key R&D projects include the development of cell-based medications as well as introduction of novel therapeutics based on Histone H1 – for treatment of oncohematological diseases. Since 2009 Cryonix projects have been supported by the Russian Ministry of Industry and Trade. For over 5 years Cryonix has  represented the interests of Gemabank in Saint Petersburg and the region. The acquisition of a controlling interest in Cryonix has been made to maximize integration between the two companies in the development and commercialization of innovative drugs and provision of high-tech medical services, including the strengthening of HSCI’s position on the market for isolation and storage of cord blood stem cells in northwest Russia.